Oregon Health & Science University (OHSU) has been selected as one of five university research centers to pioneer
development of the National Institutes of Health Toxicogenomics
Research Consortium (TRC). Representing a fundamental change in our approach to toxicology, toxicogenomics
is a revolutionary new scientific discipline that studies the role of gene-environment interactions in disease
and dysfunction. The OHSU componentspearheaded by CROET, in concert with the School of Medicine's Department
of Pediatrics and Doernbecher Childrens' Hospitalwill focus on neurotoxicogenomics and child health. Other
participants in this national consortium include research scientists at the Massachusetts Institute of Technology,
the Fred Hutchinson Cancer Research Center at the University of Washington, Duke University and the University
of North Carolina.
OHSU received the center grant as a cooperative agreement from the National
Institute of Environmental Health Sciences (NIEHS), a component of the National
Institutes of Health (NIH). NIEHS and CROET at OHSU have complementary missions
of reducing the burden of disease and dysfunction by defining how environmental
and occupational agents adversely impact health. NIEHS has slated a total of $37
million to fund the new consortium for an initial period of 5 years. OHSU will
receive $7.25 million, one-fifth of which will be used to fund collaborative studies
at the Boston Biomedical Research Institute. Last year, NIEHS awarded CROET a
Superfund Basic Research center grant that will interact with the new TRC initiative.
To conduct their research, scientists at OHSU and other participating TRC centers
will utilize genome and protein-profiling technologies. These groundbreaking methods
will allow the consortium to understand how cells of various organisms respond
to environmental factors. Chemicals that disrupt human brain development and induce
neurodegeneration are the common interest of scientists in the CROET-Pediatrics
research partnership at OHSU. The university's bioinformatics resources will play
an important role in this research by organizing and compiling the tremendous
amount of data generated by the research programs.
One of the consortium's goals is to develop standards and practices for the
newly developed science of toxicogenomics that will allow researchers to generate
consistent data in a suitably equipped laboratory anywhere in the world. The five
participating centers and NIEHS scientists will seek inter-laboratory validation
of experimental results by conducting specific experiments using common research
protocols. A TRC Steering Committee, with membership from the five cooperating
university centers, the NIEHS, and a NIEHS-appointed contractor, will oversee
the research collaboration. The Steering Committee will apply its collective knowledge
to accelerate the pace of discovery and promote the identification of gene-expression
signatures associated with chemical-induced disorders, such as organic solvent
neuropathy. Gene signatures will be entered into a publicly accessible NIH Environmental
Genome database for use in developing strategies to prevent and treat environmental
diseases.
Results gained through the synergistic interactions of researchers in the TRC
will help improve public health through better risk detection and earlier intervention
in disease processes. CROET researchers see benefits in sorting out why some chemicals
are bad actors and others not, and how workplace chemicals and other exposures
interact to trigger illness.
Exposures early in life may result in health disorders evident at birth,
during development or in later life says Dr. Peter Spencer, senior scientist
and director of CROET. A greater understanding of the impacts of natural
and synthetic chemicals on human development will minimize illness in the population
and provide for a healthier workforce. Drs. Charles Roberts and Srinavasa
Nagalla, respectively professor and assistant professor of Pediatrics in the School
of Medicine (SOM), will also play a leading role in the new research center. Other
OHSU members of the team include Richard Allen, Ph.D. (CROET) Stephen Back, M.D.
(Pediatrics, SOM), Christopher Dubay (Medical Informatics, SOM), Gregory Higgins,
Ph.D. (CROET), Michael Lasarev, M.S. (CROET), Glen Kisby, Ph.D. (CROET), Jodi
Lapidus, Ph.D. (Public Health and Preventive Medicine, SOM), and Mohammad Sabri,
Ph.D. (CROET and Neurology, SOM). Harvard Associate Professor Jeffrey Miller,
Ph.D., completes the multidisciplinary research team.